Avsola (infliximab-axxq) — FDA-Approved Biosimilar to Remicade (infliximab)
TNF-alpha Inhibitor Biosimilar (IV) · Approved 2019 · $0–$35/mo for most insured patients
🔬 What Is Avsola?
Avsola (infliximab-axxq) is an FDA-approved biosimilar to Remicade (infliximab). A biosimilar is a biological medication that is highly similar to an already-approved reference biologic, with no clinically meaningful differences in safety, purity, or potency. Avsola (infliximab-axxq) is an FDA-approved Remicade biosimilar from Amgen. It is given by intravenous (IV) infusion and approved for all Remicade indications including RA, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.
🛒 Order Avsola — Direct from BiologicHealthPlus
Our pharmacist team will contact you within 2 hours to verify your prescription and insurance.
With Insurance
$0–$35/mo for most insured patients
Amgen SupportPlus
Uninsured / PAP
Free
Income-based assistance
Avsola Overview
| Property | Details |
|---|---|
| Brand Name | Avsola |
| Generic Name | infliximab-axxq |
| Reference Biologic | Remicade (infliximab) |
| Manufacturer | Amgen |
| Drug Class | TNF-alpha Inhibitor Biosimilar (IV) |
| FDA Approval | 2019 |
| Route | IV infusion |
| Approved Conditions | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis, Crohn's Disease, Ulcerative Colitis |
| Copay Program | Amgen SupportPlus — $0–$35/mo for most insured patients |
Approved Conditions
Avsola vs Remicade (infliximab)
Avsola has been demonstrated to be biosimilar to Remicade (infliximab) through comprehensive analytical, non-clinical, and clinical studies. The FDA requires that biosimilars have no clinically meaningful differences from the reference product. Patients who are stable on Remicade (infliximab) should discuss any potential switch to Avsola with their prescriber.
| Factor | Avsola | Remicade (infliximab) |
|---|---|---|
| FDA Status | Biosimilar (approved 2019) | Reference biologic |
| Active Ingredient | infliximab-axxq | infliximab |
| Mechanism | TNF-alpha Inhibitor) | Same |
| Approved Indications | Same as Remicade (infliximab) | Multiple FDA-approved |
| Typical Patient Cost | $0–$35/mo for most insured patients | $0–$35/mo (varies by plan) |
📚 Sources & Further Reading
Medical Disclaimer: Educational content reviewed by BiologicHealthPlus Clinical Team. Last reviewed: August 2026.